Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Telemedicine Based Remote Home Monitoring After Liver Transplantation (TelehealthOLT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03878329
Recruitment Status : Completed
First Posted : March 18, 2019
Last Update Posted : July 1, 2021
Sponsor:
Information provided by (Responsible Party):
Shimul Shah, University of Cincinnati

Brief Summary:
A significant opportunity exists to involve patients and their caregivers in more effective perioperative care and transition to home for transplant patients. Stakeholders were engaged through the University of Cincinnati Liver Transplant Program to prioritize changes in improving post transplant care. The initial findings indicated that increasing "care between visits" is the top priority for patients for improving function, quality of life and independence. Building on existing telehealth research, an enhanced home management program (HMP) to leverage and improve patient self-care following liver transplantation was developed, specifically by improving adherence, reducing readmissions and improving the transition from hospital to home. The improvement of care may have profound effect in the first 90 days after transplant on important long-term health parameters that affect clinical outcomes such as depression, weight gain, blood pressure control and diabetes management. With patient engagement, a randomized controlled trial is proposed comparing traditional provider-based care vs. traditional care with HMP. These two arms will need 50 patients in each arm with a 0.5 year follow up. Patients have said that the primary outcomes are quality of life, function and independence. To that end, the primary study outcomes are assessment of adherence, readmissions (90-day), patient satisfaction. The HMP model will advise providers, health care systems, and transplant centers how to improve patient care, especially among those at greatest risk of poor outcomes specifically minorities and those of low socioeconomic status.

Condition or disease Intervention/treatment Phase
Liver Failure Liver Transplant; Complications Behavioral: remote home monitoring Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized Controlled Trial
Masking: None (Open Label)
Masking Description: Non-blinded.
Primary Purpose: Prevention
Official Title: Randomized Prospective Trial of Telemedicine Based Remote Home Monitoring After Liver Transplantation
Actual Study Start Date : January 1, 2017
Actual Primary Completion Date : January 1, 2019
Actual Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: standard of care
standard of care treatment
Experimental: remote home monitoring
use of telemedicine based remote home monitoring
Behavioral: remote home monitoring
Will use telemedicine to guide behavior changes in outcomes




Primary Outcome Measures :
  1. 90- day readmission [ Time Frame: 90 days ]
    Assess readmission



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects (≥ 18 years old) who are liver transplant recipients.
  2. Discharged home within 45 days of liver transplant.
  3. Able and willing to provide informed consent.

Exclusion Criteria:

  1. Post-transplant admission and care provided by University of Cincinnati Medical Center or rehab facility > 45 days after liver transplant.
  2. Unable to have 4G wireless connectivity or wifi in their home.
  3. Patient has any form of psychiatric disorder or a condition that, in the opinion of the investigator, may hinder communication with the investigator.
  4. Inability to cooperate or communicate with the investigator.
Publications of Results:
Layout table for additonal information
Responsible Party: Shimul Shah, Professor of Surgery, Chief, Solid Organ Transplantation, Department of Surgery, University of Cincinnati
ClinicalTrials.gov Identifier: NCT03878329    
Other Study ID Numbers: TelehealthOLT
First Posted: March 18, 2019    Key Record Dates
Last Update Posted: July 1, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Protocol will be share
Supporting Materials: Study Protocol
Time Frame: 1 year after study completed.
Access Criteria: investigator with HIPAA compliance

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Failure
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases